Affiliation:
1. Hubei Province Huangshi Puren Hospital Cardiovascular Medicine, 435002, China
2. Audit Office of Huangshi Central Hospital, Hubei Province, China
Abstract
Objective. To investigate the effects of metoprolol succinate combined with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF). Methods. About 120 patients with CHF treated from April 2018 to April 2021 were enrolled in our hospital. The patients were arbitrarily assigned into control group and study group. The control group was cured with metoprolol succinate sustained-release tablets, and the study group was cured with metoprolol succinate sustained-release tablets combined with Entresto. The curative effect, cardiac function, vascular endothelial function, oxidative stress, and coagulation function were compared. Results. First of all, we compared the general data, and there exhibited no difference in age, sex, course of disease, hypertension, coronary heart disease, diabetes, atrial fibrillation, and other general data (
). Second, we compared the clinical efficacy. The effective rate of the study group (98.33%) was higher (90.00%) (
). There exhibited no significant difference in cardiac function indexes before treatment, but after treatment, LVEF increased, LVESD and LVEDD decreased, LVESD and LVEDD in the study group were lower, and LVEF in the study group was higher (
). Before treatment, there exhibited no significant difference in vascular endothelial function. However, the levels of CGRP and ET increased and the level of NO decreased, and the level of NO in the study group was lower, while the levels of CGRP and ET in the study group were higher after treatment (
). There exhibited no significant difference in oxidative stress indexes before treatment, however, the levels of GSH-Px and SOD increased and the levels of MDA decreased after treatment, while the level of MDA in the study group was lower, while the levels of GSH-Px and SOD in the study group were higher (
). Finally, we compared the indexes of blood coagulation function. There exhibited no significant difference before treatment, but after treatment, the levels of APTT, PT, and FIB decreased, and the levels of APTT, PT, and FIB in the study group were lower (
). Conclusion. Clinical practice demonstrated that LVESD and LVEDD decreased and LVEF increased after treatment with Entresto combined with metoprolol in CHF patients, which can effectively facilitate cardiac function and vascular endothelial function, reduce oxidative stress reaction, and improve blood coagulation indexes, suggesting that Entresto combined with metoprolol can improve ventricular remodeling with good safety.
Subject
Applied Mathematics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,Modeling and Simulation,General Medicine
Reference30 articles.
1. Effects of sarcophroxtan combined with metoprolol on cardiac function, vascular endothelial function and neuroendocrine factors in elderly patients with chronic heart failure;W. Hongjuan;Chinese Journal of Gerontology,2021
2. Scientists ID new metabolic target to prevent, treat heart failure at earliest stage;Ohio State University Wexner medical center;NewsRx Health & Science,2019
3. Effects of different nutritional status on IGF-1 and IL-17 levels in elderly patients with chronic congestive heart failure;L. Wei;Chinese Journal of Gerontology,2021
4. Heart Failure With Reduced Ejection Fraction: A Review;S. P. Murphy;JAMA,2020
5. Evaluation of the efficacy of salkuridine and valsartan in patients with chronic heart failure in different course of disease;S. Jie;Journal of Clinical Cardiovascular Diseases,2021